| アブストラクト | Identifying patients at increased risk of immune-related adverse events (irAEs) facilitates safe application of immune checkpoint inhibitors (ICIs). This retrospective study aimed to determine the effect of age on the risk of irAEs in patients receiving ICIs and to identify potential mechanisms underlying age-related irAE risk differences. We analyzed reports of FDA Adverse Event Reporting System from July 1, 2014, to September 30, 2021. The information component ratio (IC(Delta)) was used to compare the irAE risk between older adults (> 65 years) and younger adults (25-65 years), of which the 95% confidential interval lower limit (IC(Delta025)) exceeding zero indicated significantly increased risk. We found that older adults had a significantly higher overall irAE risk than younger adults (IC(Delta025) 0.38), which was observed in almost all organ systems. We further analyzed the correlation between age-related irAE risks and age-related transcriptional changes to identify potential genes and pathways underlying age-related irAE risk differences. We found that genes significantly correlated with IC(Delta) were enriched in processes including extracellular matrix organization, regulation of myeloid leukocyte mediated immunity, and regulation of c-Jun N-terminal kinase (JNK) cascade. In addition, single-cell RNA sequencing analysis confirmed that genes involved in collagen-containing extracellular matrix and JNK cascade were significantly upregulated in myeloid cells from ICI-associated colitis tissues compared with ICI-treated colon tissues without colitis. In conclusion, older adults receiving ICIs have higher irAE risks than younger adults. Upregulation of genes involved in JNK cascade and collagen-containing extracellular matrix in myeloid cells may contribute to increased irAE risks in older adults. |
|---|
| ジャーナル名 | Clinical and experimental medicine |
|---|
| Pubmed追加日 | 2023/4/5 |
|---|
| 投稿者 | Yang, Kaili; Li, Jiarui; Sun, Zhao; Bai, Chunmei; Zhao, Lin |
|---|
| 組織名 | Department of Medical Oncology, Peking Union Medical College Hospital, Chinese;Academy of Medical Sciences and Peking Union Medical College, No.1 Shuai Fu Yuan,;Dongcheng District, Beijing, 100032, China.;Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and;Translational Research (Ministry of Education), Peking University Cancer Hospital;and Institute, Beijing, China.;Dongcheng District, Beijing, 100032, China. wz20010727@aliyun.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37016065/ |
|---|
